Though rare, ocular surface tumours often prove deadly

Article

In a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, Nathan Hall pointed out that an epidemiologic analysis of malignant ocular surface tumours found significant differences in geographic prevalence rates in the United States.

Reviewed by Nathan Eli Hall.

An epidemiologic analysis of malignant ocular surface tumours, which are rare but serious events, found significant differences in geographic prevalence rates in the US with more Caucasian men and smokers affected, according to Nathan Hall, MS, BS, from the Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston.

Considering the seriousness of these tumours of the conjunctiva and/or cornea, patient morbidity and mortality can be affected, Hall pointed out, noting the importance of identifying the associated risk factors, such as ultraviolet light exposure in various regions, gender, and older age that can play a role.

Nathan Hall, MS, BS

Nathan Hall, MS, BS

Hall and his colleagues conducted the analysis, which used data from the American Academy of Ophthalmology’s IRIS Registry, and included more than 15,000 patients who had been diagnosed with a malignant ocular surface tumour of the conjunctiva/cornea between 2013 and 2019.

The investigators found that prevalence rates of ocular surface tumours differed across all geographic areas, with the highest prevalence in the North Central region (0.0032 cases/100,000) and lowest in the West (0.0014 cases/100,000), Hall reported.

Investigators found that prevalence rates of ocular surface tumours differed across all geographic areas. (Image courtesy of Nathan Hall, MS, BS)

Investigators found that prevalence rates of ocular surface tumours differed across all geographic areas. (Image courtesy of Nathan Hall, MS, BS)

White males and smokers were most highly affected and non-white females were the least affected (p < 0.0001 for all comparisons). Hall also noted that smoking seems to have an impact on the prevalence because the investigators found a significantly higher proportion of current smokers within those patients with an ocular surface tumour than in the general IRIS Registry patient pool.

Investigators also pointed out that exposure to ultraviolet light and latitude-related differences have been reported previously as risk factors for ocular surface tumours in other studies, and including similar types of data in the IRIS Registry should be another path of investigation.

“Our results suggested a significantly higher prevalence of ocular surface tumours in white males and smokers, and differences between geographic area of the US,” Hall concluded.

Related Content: Additional AAO content | Cornea | Inflammation & Infection

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.